1 / 47

Discussion Outline

Discussion Outline. Cells of the Immune System. Innate Immunity. Receptors on T and B Cells Are Specific for Each Antigen. Innate and Adaptive Immune Systems. Antigen Presentation. Adaptive Immunity. Function of the Immune System. Tumor Escape Mechanisms.

genevieve-robert
Download Presentation

Discussion Outline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Discussion Outline

  2. Cells of the Immune System

  3. Innate Immunity

  4. Receptors on T and B Cells Are Specific for Each Antigen

  5. Innate and Adaptive Immune Systems

  6. Antigen Presentation

  7. Adaptive Immunity

  8. Function of the Immune System

  9. Tumor Escape Mechanisms

  10. Risk for Malignancies Is Higher in Immunosuppressed Patients With Organ Transplants Compared With in Healthy Individuals*

  11. Cancer and Immunoediting

  12. Antigen Presentation and T-Cell Priming

  13. Reasons for Failed Vaccine Studies

  14. Tumor Antigens

  15. Dual Role of the Immune System in Cancer

  16. Chimeric Antigen-Receptor T Cells for Lymphoma

  17. Multiple Costimulatory and Inhibitory Interactions Regulate T-Cell Responses

  18. CTLA-4: Negatively Modulates the Immune Response

  19. Phase 3 Trial of Ipilimumab in Melanoma

  20. Progression-Free Survival in Patients Receiving Ipilimumab for Lung Cancer

  21. Immune Checkpoints Regulate the Immune System

  22. Phase 1 Study: Activity of Nivolumab

  23. Targeted Agents Against Immune Checkpoint Pathways

  24. Antibodies to Tumor-Expressing Antigens

  25. Measuring Response With Immune Therapies

  26. Future Objectives

  27. Nivolumab + Ipilimumab in Patients With Advanced Melanoma

  28. Combination Studies of Checkpoint Inhibitors

  29. Conclusions

  30. Abbreviations

  31. Abbreviations (cont)

  32. Abbreviations (cont)

  33. References

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

More Related